Loading...
A New PqsR Inverse Agonist Potentiates Tobramycin Efficacy to Eradicate Pseudomonas aeruginosa Biofilms
Schütz, Christian Ho, Duy‐Khiet Hamed, Mostafa Mohamed Abdelsamie, Ahmed Saad Röhrig, Teresa Herr, Christian Kany, Andreas Martin Rox, Katharina Schmelz, Stefan Siebenbürger, Lorenz
Schütz, Christian
Ho, Duy‐Khiet
Hamed, Mostafa Mohamed
Abdelsamie, Ahmed Saad
Röhrig, Teresa
Herr, Christian
Kany, Andreas Martin
Rox, Katharina
Schmelz, Stefan
Siebenbürger, Lorenz
Citations
Altmetric:
Advisors
Editors
Other Contributors
Issue Date
2021-03-18
Submitted date
Files
Loading...
Open Access publication
Adobe PDF, 2.92 MB
Other Titles
Abstract
Pseudomonas aeruginosa (PA) infections can be notoriously difficult to treat and are often accompanied by the development of antimicrobial resistance (AMR). Quorum sensing inhibitors (QSI) acting on PqsR (MvfR) – a crucial transcriptional regulator serving major functions in PA virulence – can enhance antibiotic efficacy and eventually prevent the AMR. An integrated drug discovery campaign including design, medicinal chemistry‐driven hit‐to‐lead optimization and in‐depth biological profiling of a new QSI generation is reported. The QSI possess excellent activity in inhibiting pyocyanin production and PqsR reporter‐gene with IC50 values as low as 200 and 11 × 10−9 m, respectively. Drug metabolism and pharmacokinetics (DMPK) as well as safety pharmacology studies especially highlight the promising translational properties of the lead QSI for pulmonary applications. Moreover, target engagement of the lead QSI is shown in a PA mucoid lung infection mouse model. Beyond that, a significant synergistic effect of a QSI‐tobramycin (Tob) combination against PA biofilms using a tailor‐made squalene‐derived nanoparticle (NP) formulation, which enhance the minimum biofilm eradicating concentration (MBEC) of Tob more than 32‐fold is demonstrated. The novel lead QSI and the accompanying NP formulation highlight the potential of adjunctive pathoblocker‐mediated therapy against PA infections opening up avenues for preclinical development.
Citation
Adv. Sci. 2021, 2004369. https://doi.org/10.1002/advs.202004369.
Publisher
Journal
PubMed ID
PubMed Central ID
Additional Links
Embedded video
Type
Article
Language
en
Description
Series/Report no.
ISSN
2198-3844
EISSN
2198-3844
ISBN
ISMN
Gov't Doc #
Sponsors
H2020 Marie Skłodowska-Curie Actions
License
Attribution 4.0 International